Catalyst Pharmaceuticals logo

Catalyst PharmaceuticalsNASDAQ: CPRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 November 2006

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.46 B
-14%vs. 3y high
83%vs. sector
-55%vs. 3y high
29%vs. sector
-50%vs. 3y high
74%vs. sector
-49%vs. 3y high
63%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:45:14 GMT
$20.66-$0.59(-2.78%)

Dividend

No data over the past 3 years
$128.69 M$133.71 M
$128.69 M$43.88 M

Analysts recommendations

Institutional Ownership

CPRX Latest News

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com19 November 2024 Sentiment: POSITIVE

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
zacks.com15 November 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
globenewswire.com13 November 2024 Sentiment: POSITIVE

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
zacks.com07 November 2024 Sentiment: POSITIVE

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.

CPRX vs. STVN: Which Stock Is the Better Value Option?
zacks.com06 November 2024 Sentiment: NEUTRAL

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
globenewswire.com22 October 2024 Sentiment: NEUTRAL

The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET

CPRX or STVN: Which Is the Better Value Stock Right Now?
zacks.com21 October 2024 Sentiment: NEUTRAL

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

New Strong Buy Stocks for October 8th
zacks.com08 October 2024 Sentiment: POSITIVE

CPRX, HCI, DXC, CRAI and CRUS have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2024.

CPRX or STVN: Which Is the Better Value Stock Right Now?
zacks.com04 October 2024 Sentiment: NEUTRAL

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?

Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
zacks.com02 October 2024 Sentiment: POSITIVE

If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What type of business is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

What sector is Catalyst Pharmaceuticals in?

Catalyst Pharmaceuticals is in the Healthcare sector

What industry is Catalyst Pharmaceuticals in?

Catalyst Pharmaceuticals is in the Biotechnology industry

What country is Catalyst Pharmaceuticals from?

Catalyst Pharmaceuticals is headquartered in United States

When did Catalyst Pharmaceuticals go public?

Catalyst Pharmaceuticals initial public offering (IPO) was on 08 November 2006

What is Catalyst Pharmaceuticals website?

https://www.catalystpharma.com

Is Catalyst Pharmaceuticals in the S&P 500?

No, Catalyst Pharmaceuticals is not included in the S&P 500 index

Is Catalyst Pharmaceuticals in the NASDAQ 100?

No, Catalyst Pharmaceuticals is not included in the NASDAQ 100 index

Is Catalyst Pharmaceuticals in the Dow Jones?

No, Catalyst Pharmaceuticals is not included in the Dow Jones index

When was Catalyst Pharmaceuticals the previous earnings report?

No data

When does Catalyst Pharmaceuticals earnings report?

The next expected earnings date for Catalyst Pharmaceuticals is 28 February 2025